Fmr Llc - Feb 13, 2024 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Other*
Signature
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
BEAM
Transactions as of
Feb 13, 2024
Transactions value $
-$27,545,051
Form type
4
Date filed
2/15/2024, 02:34 PM
Previous filing
Jan 31, 2024
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Sale -$12.4K -410 -0.01% $30.28 2.77M Feb 13, 2024 Shares held by persons and entities whose shares are subject to reporting by the undersigned
transaction BEAM Common Stock Sale -$35.7K -1.16K -0.04% $30.93 2.77M Feb 13, 2024 Shares held by persons and entities whose shares are subject to reporting by the undersigned
transaction BEAM Common Stock Sale -$26.1M -854K -40.01% $30.51 1.28M Feb 14, 2024 F-Prime Capital Partners Healthcare Fund V LP F1
transaction BEAM Common Stock Sale -$1.43M -45.7K -3.57% $31.34 1.24M Feb 14, 2024 F-Prime Capital Partners Healthcare Fund V LP F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Fmr Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $30.25 to $31.25. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $31.25 to $31.58. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager.